FDA Approves Pembrolizumab for Refractory or Relapsed Classical Hodgkin Lymphoma
Mar 13
2017
The U.S. Food and Drug Administration granted accelerated approval to pembrolizumab (KEYTRUDA®, Merck and Co., Inc.) for the treatment of adult and pediatric patients with refractory classical Hodgkin lymphoma (cHL), or those who have relapsed after three or more prior lines of therapy.
